Table 2 Pioglitazone treatment results... | American Society of Hematology

Table 2

Pioglitazone treatment results in faster resolution of neutrophilia in CGD and WT mice

Condition*	ψ_max, ×10⁶	T_max, h	T₅₀, h	R_i, h	I_pmn=mono, h
WT-Veh	22.9 ± 4.3	18 ± 2.5	30 ± 2.2	12 ± 0.8	32 ± 2.2
WT-Pio	21.9 ± 2.5	16 ± 2.2	24 ± 1.5†	8 ± 2.2†	24 ± 2.5†
CGD-Veh	35.2 ± 4.7*	22 ± 2.18	60 ± 1.7‡	36 ± 1.8‡	78 ± 1.8‡
CGD-Pio	24.7 ± 2.5§	20 ± 1.1	36 ± 2.3§	16 ± 1.9§	40 ± 1.9§

Condition*	ψ_max, ×10⁶	T_max, h	T₅₀, h	R_i, h	I_pmn=mono, h
WT-Veh	22.9 ± 4.3	18 ± 2.5	30 ± 2.2	12 ± 0.8	32 ± 2.2
WT-Pio	21.9 ± 2.5	16 ± 2.2	24 ± 1.5†	8 ± 2.2†	24 ± 2.5†
CGD-Veh	35.2 ± 4.7*	22 ± 2.18	60 ± 1.7‡	36 ± 1.8‡	78 ± 1.8‡
CGD-Pio	24.7 ± 2.5§	20 ± 1.1	36 ± 2.3§	16 ± 1.9§	40 ± 1.9§

Mice were treated as described in Figure 5 and parameters determined as described in Table 1.

P ≤ .03 compared to WT vehicle-treated mice.

P ≤ .04 compared to CGD vehicle-treated mice.